| Literature DB >> 27590105 |
Saro H Armenian1, Wassim Chemaitilly2, Marcus Chen3, Eric J Chow4, Christine N Duncan5, Lee W Jones6, Michael A Pulsipher7, Alan T Remaley3, Alicia Rovo8, Nina Salooja9, Minoo Battiwalla10.
Abstract
A number of studies have shown that autologous and allogeneic hematopoietic cell transplantation (HCT) contribute to an increased incidence of cardiovascular disease (CVD) and worsening of cardiovascular risk factors that could contribute to further CVD over time. These observations, combined with a notable increase in the number of survivors after HCT in recent years, highlight the need for studies aimed at modifying risk or preventing these outcomes by changing specific approaches and/or post-HCT interventions. To address these issues, the National Heart, Lung and Blood Institute and National Cancer Institute co-sponsored an international initiative on late effects after HCT. This report summarizes the major gaps in knowledge along with detailed recommendations regarding study priorities from the Cardiovascular Disease and Associated Risk Factors Committee, a multidisciplinary panel of international experts. The committee calls for specific studies aimed at understanding and preventing arterial disease and cardiac dysfunction (heart failure, valvular disease, and arrhythmias), as well as decreasing cardiovascular risk factors (hypertension, hyperglycemia, dyslipidemia, and sarcopenic obesity) after HCT.Entities:
Keywords: Cardiovascular disease; Cardiovascular risk factors; Chronic disease; Hematopoietic cell transplantation; Late effects; National Institutes of Health consensus; Survivorship
Mesh:
Year: 2016 PMID: 27590105 PMCID: PMC5526451 DOI: 10.1016/j.bbmt.2016.08.019
Source DB: PubMed Journal: Biol Blood Marrow Transplant ISSN: 1083-8791 Impact factor: 5.742